CoChat

Adrenal Suppression with Aminoglutethimide. II. Differential Effects of Aminoglutethimide on Plasma Androstenedione and Estrogen Levels12

SAMOJLIK, E., SANTEN, R. J., WELLS, S. A. · 1977 · The Journal of Clinical Endocrinology & Metabolism
Cited by 95

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

A regimen of adrenal suppression using aminoglutethimide in combination with hydrocortisone was developed as treatment of women with metastatic breast carcinoma. In order to determine the degree of suppression and the site or sites of estrogen blockade, we measured androstenedione, estrone, and estradiol plasma levels in castrate and non-castrate postmenopausal women with metastatic breast carcinoma during this therapy. During the initial 2 weeks of treatment, plasma androstenedione levels increased significantly from 570 ± 70 to 950 ± 160 pg/ml (P < .05) and then gradually fell to a nadir of 230 ± 50 pg/ml (P < .001) during chronic therapy with 40 mg of hydrocortisone and 1000 mg of aminoglutethimide. In contrast, estrone levels decreased abruptly with the initiation of therapy from basal levels of 43.7 ±11.2 pg/ml to 13.5 ± 1.6 pg/ml (P < .02) and during chronic drug administration to 9.3 ± 1.0 pg/ml (P < .001). Similarly, estradiol fell from 17.5 ± 4.1 to 5.5 ± 1.0 pg/ml (P < .01) initially and to 5.0 ± 0.5 pg/ml (P < .01) over a 6-12 month period. The dichotomy between high androstenedione and suppressed estrone early in therapy suggested that aminoglutethimide might block the extra-adrenal conversion of androstenedione to estrone. Continued production of various steroids by the postmenopausal ovary could influence the degree of estrogen suppression in individual patients. To examine this possibility, a subgroup of 5 women with spontaneous menopause was compared to 8 surgically castrate postmenopausal patients. Although the basal levels of estrone and estradiol were slightly higher in spontaneously postmenopausal women, the concentrations of these estrogens were not statistically significantly different from those in castrate women with breast carcinoma or in control groups of normal postmenopausal women or women with endometrial carcinoma. Basal androstenedione levels were similar in all groups. However, during each phase of aminoglutethimide therapy in women with breast carcinoma, androstenedione concentrations appeared to be higher in patients with postmenopausal ovaries than in surgically castrate subjects. These observations suggested thai the postmenopausal ovaries contributed significantly to androstenedione secretion in patients receiving aminoglutethimide. On the other hand, estrone and estradiol were suppressed similarly during medical adrenalectomy in postmenopausal women with oi without ovaries. In these two patient groups, nadii levels of estrone were 9.4 ± 2.3 pg/ml and 9.3 ± 1.1 pg/ml and of estradiol, 4.0 ±1.3 and 5.3 ± 0.6 pg/ml. respectively. These observations demonstrate that estrogen production is inhibited before total adrenal blockade is accomplished during the initial phases ol therapy and suggest that aminoglutethimide might block the peripheral conversion of androstenedione to estrone. This factor may provide a margin of safety in patients who lack rigid compliance to the established drug regimen. Our data also indicate that the ovaries in postmenopausal women are capable of contributing to androstenedione production.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jcem-45-3-480

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 95

Metadata

Authors
SAMOJLIK, E., SANTEN, R. J., & WELLS, S. A.
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
1977-09
Volume
45
Issue
3
Pages
480-487
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W2158768192
Cited by
95
References
1
FWCI
5.95
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.